“My son’s lips, at this point, started to turn blue. He also had a febrile seizure, which is why his body was stiff and ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season.

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

The virus is a common respiratory illness that infects the lungs and airways. Most people experience mild symptoms, like the common cold. However, RSV can cause more severe symptoms in infants, older ...